Appetite quiets down
Most patients notice cravings, snacking and food noise drop within days of starting.
Microdosing keeps GLP-1 and GIP receptors gently activated without the appetite suppression of higher doses. The result is improved insulin sensitivity, steadier energy, better sleep, and a quieter inflammatory baseline — without the trade-offs of full clinical doses.
Six-month trajectories from clinical data of the underlying molecules. GLP-1 produces continued, compounding loss; lifestyle changes alone tend to plateau and rebound.
Every body is different. These are the patterns we see most often across thousands of women on this protocol.
Most patients notice cravings, snacking and food noise drop within days of starting.
Body-weight reduction starts showing up on the scale and in how clothes fit.
Steady weekly loss with provider-guided dose titration. Mood and energy stabilize.
Average 15–20% body weight reduction in clinical data, with maintenance protocols built in.
Quick health questionnaire — about 5 minutes. We use it to match you to the right medication and dose.
A US-licensed clinician reviews your full profile and either prescribes or comes back with a question.
Your medication arrives free of charge with everything you need to start. Provider support is included.
Some patients lose modest weight (5–10 lbs over 6 months). The primary goal is metabolic balance, not aggressive weight loss.
Microdosing uses a fraction of the standard clinical dose. You get the metabolic and longevity benefits with far fewer GI side effects.